Escitalopram in 8-week open-label treatment of post-stroke depression: the efficacy, safety and the effect on regional brain function

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019366

Enrollment

Unknown

Registered

2018-11-07

Start date

2018-11-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke depression

Interventions

aphasia cohort versus non-aphasia cohort:escitalopram

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male and female inpatients aged = 18 years; 2. First episode of acute ischemic stroke met WHO stroke criteria occurred within previous 14 days (confirmed by MRI or CT); 3. Fulfill the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) defined major depressive disorder (MDD); 4. The score of SADQ-H = 26 at screening; 5. Have clear consciousness with stable stroke condition to complete scale assessment; 6. Agree to participate in the study with written informed consent provided by patients or their legal guardians.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of diagnosed depression or other psychiatric diseases (schizophrenia, bipolar disorders, substance- related and addictive disorders, etc.) before stroke episode; 2. Patients with dementia or other known cognitive dysfunction resulted from neurological disorders; 3. Patients comorbid with severe or life-threatening medical conditions, such as severe Parkinsons disease, or terminal stage cancer; 4. Patients with a history of QT prolongation, long QT syndrome, auricular fibrillation, previously treated angle closure glaucoma, liver or renal dysfunction, and epilepsy; 5. Patients are being treated with drugs interfering with depression assessment, such as anti-epilepsy, sedative hypnotic, anticholinergics and interferon, etc.; 6. Patients are being treated with class I antiarrhythmic agents, non-selective irreversible MAIOs, linezolid, pimozide, or have joined other clinical trials; 7. Patients with high risk of suicide; 8. Pregnant or lactation women, or women recently plan to have pregnancy.

Design outcomes

Primary

Measure	Time frame
Stroke Aphasic Depression Questionnaire;	—

Countries

China

Contacts

Public ContactWang Chun-Xue

Beijing Tiantan Hospital, Capital Medical University

snowsen@126.com+86 13701193710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026